The European Commission (EC) approved Regeneron Pharmaceuticals, Inc.REGN and its partner Sanofi’s SNY low density lipoprotein (LDL) cholesterol lowering medication, Praluent. The EC approved Praluent for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia as an adjunct
Regeneron/Sanofi's PCSK9 Inhibitor Praluent Approved in EU
